Skip Navigation

Rheumatoid arthritis (refractory) - abatacept

Abatacept for the treatment of rheumatoid arthritis

Guidance type:  Technology appraisal
Date issued:  April 2008

We will consult on our review plans for this guidance in July 2010.

Reference:  TA141

Summary

Abatacept is not recommended for people with moderate to severe active rheumatoid arthritis who have already tried drugs known as disease-modifying anti-rheumatic drugs (including a 'TNF inhibitor'drug), which didn't work or weren't suitable.
Healthcare professionals should not stop prescribing abatacept for people who were already taking it when the guidance was issued. These patients should be able to carry on taking abatacept until they and their specialist decide that it is the right time to stop treatment.

Top

Documents

For healthcare professionals

For patients, carers and the public

Background information

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

Top

Search NICE guidance


Advanced guidance search

Related guidance

Click the links below to see guidance on similar topics